Novomix 50 Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 50 Flexpen, is an insulin analog presented as a rapid‑acting formulation for subcutaneous injection use. It lowers blood glucose in people with diabetes mellitus. GNH USA supplies Novomix 50 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novomix 50 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novomix 50 Flexpen is an insulin analog that acts on the glucose regulation pathway in diabetes management. - Type 1 diabetes mellitus: improves basal and prandial glycaemic control. - Type 2 diabetes mellitus: assists in achieving target blood glucose levels when oral agents are insufficient. - Gestational diabetes mellitus: helps maintain maternal glucose control during pregnancy.

Adverse reactions to Novomix 50 Flexpen are reported across a spectrum of frequency.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in fat tissue under the skin. - Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects: - Severe hypoglycaemia: neuroglycopenic symptoms requiring assistance. - Allergic reaction: urticaria, angio‑edema or anaphylaxis. - Hypersensitivity to excipients. - Persistent hyperglycaemia despite therapy. - Unexplained edema. - Acute insulin resistance.

Novomix pens ​  ​       ​      ​     …  …  ...  ...  … … … … … … … … … …  … … 

-   t  \\